Myovant Sciences (NYSE: MYOV)
Some price data may be temporarily unavailable.
Myovant Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Myovant Sciences Company Info
Myovant Sciences is a biotech company that develops new treatments for infertility in women and prostate cancer in men. The company's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women’s health. Myovant Sciences was established in 2016 and is based in Brisbane, California.
News & Analysis
Why Myovant Sciences Stock Is Skyrocketing Today
Myovant said "no thanks" to an acquisition offer in hopes to fetch a higher price.
Why Myovant Sciences Stock Is Crashing Today
The FDA has identified deficiencies with Myovant's regulatory filing for Myfembree.
Here's Why Myovant Sciences Stock Is Falling Today
Second-quarter earnings results were a little bit disappointing.
Why Myovant Sciences Stock Is Soaring Today
Investors are cheering a big collaboration with Pfizer.
Myovant Squares Off with AbbVie On Endometriosis Treatment
With positive clinical trial results and a confirmatory study expected to report this quarter, investors should dig in.
Myovant's Uterine Fibroid Drug Relugolix Produces Positive Data in a Long-Term Study
The results were consistent with a pair of shorter studies of the combination treatment.
Why Myovant Stock Fell 5% in 2019
Shares swung wildly as investors tried to guess at the long-run prospects of promising new drug treatments for prostate cancer.
Is Myovant's New Prostate Cancer Drug a Game Changer?
Relugolix has the potential to be a blockbuster drug in two markets, but it faces competition in both.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.